De Niet, 43 patient vitamin D late treatment RCT: 45% faster recovery [p=0.06] and 50% shorter hospitalization [p=0.003] https://c19p.org/deniet
copied to clipboard
Positive Effects of Vitamin D Supplementation in Patients Hospitalized for COVID-19: A Randomized, Double-Blind, Placebo-Controlled Trial
RCT with 21 vitamin D and 22 placebo hospitalized patients in Belgium with vitamin D deficiency, showing significantly shorter hospitalization and improved clinical recovery with treatment.
|
risk of death, 65.1% lower, RR 0.35, p = 0.61, treatment 1 of 21 (4.8%), control 3 of 22 (13.6%), NNT 11, COVID-19 mortality.
|
|
risk of death, 39.7% higher, RR 1.40, p = 0.70, treatment 4 of 21 (19.0%), control 3 of 22 (13.6%), all cause including after discharge and non-COVID-19.
|
|
risk of ICU admission, 58.1% lower, RR 0.42, p = 0.41, treatment 2 of 21 (9.5%), control 5 of 22 (22.7%), NNT 7.6.
|
|
ICU time, 67.7% lower, relative time 0.32, p = 0.47, treatment 21, control 22.
|
|
risk of no hospital discharge, 79.6% lower, RR 0.20, p = 0.49, treatment 0 of 21 (0.0%), control 2 of 22 (9.1%), NNT 11, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 36.
|
|
risk of no hospital discharge, 85.4% lower, RR 0.15, p = 0.23, treatment 0 of 21 (0.0%), control 3 of 22 (13.6%), NNT 7.3, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 28.
|
|
risk of no hospital discharge, 85.4% lower, RR 0.15, p = 0.23, treatment 0 of 21 (0.0%), control 3 of 22 (13.6%), NNT 7.3, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 21.
|
|
risk of no hospital discharge, 65.1% lower, RR 0.35, p = 0.61, treatment 1 of 21 (4.8%), control 3 of 22 (13.6%), NNT 11, day 14.
|
|
risk of no hospital discharge, 65.1% lower, RR 0.35, p = 0.03, treatment 4 of 21 (19.0%), control 12 of 22 (54.5%), NNT 2.8, day 7.
|
|
recovery time, 45.4% lower, relative time 0.55, p = 0.06, treatment 21, control 22, fever.
|
|
hospitalization time, 50.0% lower, relative time 0.50, p = 0.003, treatment 21, control 22.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
De Niet et al., 7/26/2022, Double Blind Randomized Controlled Trial, placebo-controlled, Belgium, peer-reviewed, 16 authors, study period August 2020 - August 2021, dosage 25,000IU days 1-4, 11, 18, 25, trial NCT04636086 (history).
Contact:
sdeni@smb.be (corresponding author), mtrem@smb.be, mcoff@smb.be, afrouseau@chuliege.be, d.calmes@chuliege.be, affrix@chuliege.be, f.gester@chuliege.be, muriel.delvaux@chuliege.be, af.dive@chuliege.be, elora.guglielmi@chuliege.be, monique.henket@chuliege.be, alicia.staderoli@chuliege.be, renaud.louis@chuliege.be, j.guiot@chuliege.be, dmaesen@chuliege.be, etienne.cavalier@chu.ulg.ac.be.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.